Literature DB >> 11353617

Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999--2000, including a comparison of resistance rates since 1994--1995.

G V Doern1, K P Heilmann, H K Huynh, P R Rhomberg, S L Coffman, A B Brueggemann.   

Abstract

A total of 1,531 recent clinical isolates of Streptococcus pneumoniae were collected from 33 medical centers nationwide during the winter of 1999--2000 and characterized at a central laboratory. Of these isolates, 34.2% were penicillin nonsusceptible (MIC > or = 0.12 microg/ml) and 21.5% were high-level resistant (MIC > or = 2 microg/ml). MICs to all beta-lactam antimicrobials increased as penicillin MICs increased. Resistance rates among non-beta-lactam agents were the following: macrolides, 25.2 to 25.7%; clindamycin, 8.9%; tetracycline, 16.3%; chloramphenicol, 8.3%; and trimethoprim-sulfamethoxazole (TMP-SMX), 30.3%. Resistance to non-beta-lactam agents was higher among penicillin-resistant strains than penicillin-susceptible strains; 22.4% of S. pneumoniae were multiresistant. Resistance to vancomycin and quinupristin-dalfopristin was not detected. Resistance to rifampin was 0.1%. Testing of seven fluoroquinolones resulted in the following rank order of in vitro activity: gemifloxacin > sitafloxacin > moxifloxacin > gatifloxacin > levofloxacin = ciprofloxacin > ofloxacin. For 1.4% of strains, ciprofloxacin MICs were > or = 4 microg/ml. The MIC(90)s (MICs at which 90% of isolates were inhibited) of two ketolides were 0.06 microg/ml (ABT773) and 0.12 microg/ml (telithromycin). The MIC(90) of linezolid was 2 microg/ml. Overall, antimicrobial resistance was highest among middle ear fluid and sinus isolates of S. pneumoniae; lowest resistance rates were noted with isolates from cerebrospinal fluid and blood. Resistant isolates were most often recovered from children 0 to 5 years of age and from patients in the southeastern United States. This study represents a continuation of two previous national studies, one in 1994--1995 and the other in 1997--1998. Resistance rates with S. pneumoniae have increased markedly in the United States during the past 5 years. Increases in resistance from 1994--1995 to 1999--2000 for selected antimicrobial agents were as follows: penicillin, 10.6%; erythromycin, 16.1%; tetracycline, 9.0%; TMP-SMX, 9.1%; and chloramphenicol, 4.0%, the increase in multiresistance was 13.3%. Despite awareness and prevention efforts, antimicrobial resistance with S. pneumoniae continues to increase in the United States.

Entities:  

Mesh:

Year:  2001        PMID: 11353617      PMCID: PMC90537          DOI: 10.1128/AAC.45.6.1721-1729.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  The emergence of Streptococcus pneumoniae resistant to macrolide antimicrobial agents: a 6-year population-based assessment.

Authors:  K Gay; W Baughman; Y Miller; D Jackson; C G Whitney; A Schuchat; M M Farley; F Tenover; D S Stephens
Journal:  J Infect Dis       Date:  2000-10-09       Impact factor: 5.226

2.  Alterations in PBP 1A essential-for high-level penicillin resistance in Streptococcus pneumoniae.

Authors:  A M Smith; K P Klugman
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

3.  Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study.

Authors:  G V Doern; A Brueggemann; H P Holley; A M Rauch
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

4.  Relapsing pneumococcal meningitis: isolation of an organism with decreased susceptibility to penicillin G.

Authors:  S Naraqi; G P Kirkpatrick; S Kabins
Journal:  J Pediatr       Date:  1974-11       Impact factor: 4.406

5.  Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States.

Authors:  C G Whitney; M M Farley; J Hadler; L H Harrison; C Lexau; A Reingold; L Lefkowitz; P R Cieslak; M Cetron; E R Zell; J H Jorgensen; A Schuchat
Journal:  N Engl J Med       Date:  2000-12-28       Impact factor: 91.245

6.  Novel mechanism of macrolide resistance in Streptococcus pneumoniae.

Authors:  V D Shortridge; R K Flamm; N Ramer; J Beyer; S K Tanaka
Journal:  Diagn Microbiol Infect Dis       Date:  1996-10       Impact factor: 2.803

7.  Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America.

Authors:  A Tait-Kamradt; T Davies; P C Appelbaum; F Depardieu; P Courvalin; J Petitpas; L Wondrack; A Walker; M R Jacobs; J Sutcliffe
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

Review 8.  Pneumococcal resistance to antibiotics.

Authors:  K P Klugman
Journal:  Clin Microbiol Rev       Date:  1990-04       Impact factor: 26.132

9.  Penicillin-binding proteins 2b and 2x of Streptococcus pneumoniae are primary resistance determinants for different classes of beta-lactam antibiotics.

Authors:  T Grebe; R Hakenbeck
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

10.  Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system.

Authors:  J Sutcliffe; A Tait-Kamradt; L Wondrack
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

View more
  108 in total

1.  Phenotypes and genotypes of erythromycin-resistant pneumococci in Italy.

Authors:  Maria Pia Montanari; Marina Mingoia; Ileana Cochetti; Pietro Emanuele Varaldo
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

2.  Phenotypic and molecular characterization of tetracycline- and erythromycin-resistant strains of Streptococcus pneumoniae.

Authors:  Maria P Montanari; Ileana Cochetti; Marina Mingoia; Pietro E Varaldo
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

3.  In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms.

Authors:  Laurel S Almer; Jennifer B Hoffrage; Erika L Keller; Robert K Flamm; Virginia D Shortridge
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

4.  Pathophysiology and treatment of bacterial meningitis.

Authors:  Olaf Hoffman; R Joerg Weber
Journal:  Ther Adv Neurol Disord       Date:  2009-11       Impact factor: 6.570

5.  Prevalence and molecular analysis of macrolide and fluoroquinolone resistance among isolates of Streptococcus pneumoniae collected during the 2000-2001 PROTEKT US Study.

Authors:  Steven D Brown; David J Farrell; Ian Morrissey
Journal:  J Clin Microbiol       Date:  2004-11       Impact factor: 5.948

6.  Reasons for coming to hospital after treatment for community-acquired pneumonia on an ambulatory basis.

Authors:  Mohammedreza Shariatzadeh; Thomas J Marrie
Journal:  Can Respir J       Date:  2006-04       Impact factor: 2.409

7.  Increase of the M phenotype among erythromycin-resistant Streptococcus pneumoniae isolates from Spain related to the serotype 14 variant of the Spain9V-3 clone.

Authors:  C Ardanuy; A Fenoll; S Berrón; L Calatayud; J Liñares
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

8.  Pharmacodynamic profile of telithromycin against macrolide- and fluoroquinolone-resistant Streptococcus pneumoniae in a neutropenic mouse thigh model.

Authors:  Pamela R Tessier; Holly M Mattoes; Prachi K Dandekar; Charles H Nightingale; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

9.  Antibacterial activity and mechanism of action of a novel anilinouracil-fluoroquinolone hybrid compound.

Authors:  Michelle M Butler; William A Lamarr; Kimberly A Foster; Marjorie H Barnes; Donna J Skow; Patrick T Lyden; Lauren M Kustigian; Chengxin Zhi; Neal C Brown; George E Wright; Terry L Bowlin
Journal:  Antimicrob Agents Chemother       Date:  2006-10-30       Impact factor: 5.191

10.  Risk factors associated with colonization by pneumococci with reduced susceptibility to fluoroquinolones in adult outpatients.

Authors:  M Raquel Marín Jiménez; Juan Luis Muñoz Bellido; José Angel García Rodríguez
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.